Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored immunotherapies for cancer treatment, has received approval for its investigational new drug application from the U.S. Food & Drug Administration

Kiromic BioPharma, Inc. has made a significant announcement regarding its clinical initiatives. The company, a pioneer in the field of biotherapeutics, is utilizing its exclusive DIAMOND® artificial intelligence

Iksuda Therapeutics, a company specializing in the development of innovative antibody drug conjugates with enhanced tumor specificity, has announced a significant milestone in its clinical trials. The first patient has successfully completed the initial treatment cycle of IKS014, an antibody-drug

Amgen, a company listed on NASDAQ under the symbol AMGN, has unveiled the findings from the global Phase 2 DeLLphi-301 study. This study assessed the efficacy of tarlatamab

Rise Therapeutics, a biotechnology company specializing in the development of novel oral immunotherapeutics, has announced that the U.S. Food and Drug Administration has approved its investigational new drug

Qnovia, Inc., a pharmaceutical company specializing in the development of inhaled therapeutic products across various medical fields, has announced a collaborative effort with the University of Virginia to advance innovative inhaled drug candidates

Mablink Bioscience, a biotechnology company that focuses on advancing next-generation antibody-drug conjugates through its proprietary PSARLink™ platform, has announced its acquisition by Eli Lilly and Company.

Vaxcyte, Inc, has announced that the U.S. Food and Drug Administration has granted approval for the company's Investigational New Drug application for VAX-31, a 31-valent pneumococcal conjugate vaccine

Bolt Biotherapeutics has initiated its first-in-human Phase 1/2 clinical trial by dosing the inaugural patient with BDC-3042, a monoclonal antibody designed to repolarize tumor-associated macrophages (TAMs) for the purpose of combating cancer

SOTIO, a clinical-stage immuno-oncology company owned by PPF Group, has recently entered into a license and option agreement with Synaffix B.V., a subsidiary of Lonza, to develop next-generation antibody-drug